Testicular germ cell tumors

Bridges, Benjamin B.; Hussain, Arif

doi:10.1097/cco.0b013e3280ad43df

Cited by 4 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These tumors arise from dysfunctional gonocytes, the so-called carcinoma in situ (CIS) cells [ 29 ] which remain quiescent during infancy and start proliferating at puberty to give rise to either seminoma, non seminoma or combined tumors [ 30 ]. It is known that TGCT are curable in most cases, yet effective therapies for advanced stages of the disease and for recurrent germ cells tumors still need to be developed [ 31 ]. As gonocytes resemble in many aspects the spermatogonial stem cells [ 32 ], and CIS and seminoma are very similar, our findings may suggest a potential use of CAP for the management of TGCT.…”

Section: Discussionmentioning

confidence: 99%

Spermatogonial stem cell sensitivity to capsaicin: An in vitro study

Mizrak

Gadella

Erdost

et al. 2008

Reprod Biol Endocrinol

View full text Add to dashboard Cite

Background: Conflicting reports have been published on the sensitivity of spermatogenesis to capsaicin (CAP), the pungent ingredient of hot chili peppers. Here, the effect of CAP on germ cell survival was investigated by using two testis germ cell lines as a model. As CAP is a potent agonist of the transient receptor potential vanilloid receptor 1 (TRPV1) and no information was available of its expression in germ cells, we also studied the presence of TRPV1 in the cultured cells and in germ cells in situ.

show abstract

Section: Discussionmentioning

confidence: 99%

Spermatogonial stem cell sensitivity to capsaicin: An in vitro study

Mizrak

Gadella

Erdost

et al. 2008

Reprod Biol Endocrinol

View full text Add to dashboard Cite

show abstract

“…Non-seminomas can be further classified histologically into embryonal carcinomas, teratomas (mature and immature), choriocarcinomas, yolk sac tumors, and tumors with mixed histological features (2). Prognosis and choice of the adequate therapeutic regimen are dependant on tumor stage and additional clinical criteria, in particular with regard to the extent of tumor marker elevation (3)(4)(5)(6). Testicular germ cell tumors are thought to be derived from cells in the germ cell lineage at different stages of development, which are blocked in maturation (2).…”

Section: Introductionmentioning

confidence: 99%

Elevated serum levels of IGF-binding protein 2 in patients with non-seminomatous germ cell cancer: correlation with tumor markers α-fetoprotein and human chorionic gonadotropin

Fottner

Sattarova

Hoffmann

et al. 2008

European Journal of Endocrinology

View full text Add to dashboard Cite

Background/aims: Alterations of the IGF system have been described in several different types of cancer. However, no information is available about the role of the IGF system in patients with nonseminomatous germ cell cancer. Methods: Free IGF-I, IGF-II, acid-labile subunit, and IGF-binding proteins (IGFBPs) 1-4 were analyzed by specific RIAs in 32 patients with untreated non-seminomas and compared with IGFBP levels of 38 healthy controls. Serum IGFBPs were analyzed by western ligand blotting (WLB) and immunoblotting. In 16 patients, IGFBP profiles were measured before, during, and after treatment. Results: In patients with testicular cancer, IGF-II levels were on average 1.44-fold higher than in the healthy control group (1027G48 ng/ml versus 711G30 ng/ml, P!0.0001). IGFBP-2 levels were on average 2.6-fold higher (586G58 ng/ml versus 226G17 ng/ml, P!0.001). During follow-up, a decrease in IGFBP-2 levels was observed in all successfully treated patients, which correlated closely with a decrease in the tumor markers a-fetoprotein and human chorionic gonadotropin. Additionally, in all patients with recurrent disease, a significant further increase in IGFBP-2 levels (from 358G97 to 976G 260 ng/ml) was detected. IGFBP-3 levels, as measured by RIA, were not different in patients with testicular cancer compared with controls. However, WLB analysis demonstrated markedly decreased intact IGFBP-3 bands in untreated patients and a significant increase after successful therapy. Conclusion: Our results demonstrate that markedly elevated IGF-II and IGFBP-2 serum levels in patients with non-seminomatous germ cell cancer, showing a significant decrease after successful therapy and an increase in recurrent disease. Additionally, indirect evidence points to an increased proteolytic activity for IGFBP-3 in untreated testicular cancer patients.

show abstract

“…In this article, we discuss the impact of anti-cancer drugs and radiotherapy on fertility, along with the choices available for adult and pediatric cancer populations to preserve their fertility, the legal hurdles faced in providing care, and the role that clinicians from various branches may play in removing those hurdles. By analyzing the common cancer types and the ones requiring aggressive therapy in Table 1, we can focus on what types of cancer should special attention be paid to in terms of fertility preservation [5][6][7][8][9][10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Filling the Gaps in Oncofertility Care by Addressing Challenges Faced by Patients and Providers

Ranjith,

Dave

2023

Cureus

View full text Add to dashboard Cite

With enhanced technology and upcoming treatment strategies in the cancer field, the survival rates of patients have increased. We have now reached a stage in the treatment of cancer where we not only address the disease but also address complications that arise due to the disease and the side effects that present in the post-survival population due to its treatment. One of the primary consequences after oncotherapy is infertility, which is a major reason for distress for patients' post-survival, as they are afraid they may be deemed as less desirable, be rejected by their existing partner, or cannot grapple with the fact that they cannot have children of their own. This can be avoided by the implementation of proper oncofertility practices. The subject of oncofertility involves interactions between experts in the domains of cancer diagnosis, therapy, fertility preservation, and reproductive health. It attempts to investigate and broaden the possibilities for cancer survivors' reproductive future in order to suit their needs according to their ethical religious and sociocultural beliefs. However, these practices are often not implemented effectively due to ineffective doctor-patient communication, lack of knowledge, or partial knowledge of clinicians themselves regarding fertility care. This leads to a feeling of insecurity among clinicians hence resulting in them not referring patients. Lack of awareness among doctors of different oncofertility procedures available especially for patient groups like women and younger patients, hence leading to reduced referral in these groups. Improper coordination across health departments, patient ignorance regarding procedures, financial instability especially in a country with a lower sociodemographic index like India, and neglect or less importance given to the related ethical, social, and legal issues. In this article, we cover the effects of cancer and cancer treatment on fertility, the options available to adult and pediatric cancer patients to preserve their fertility like oocyte/ovarian tissue cryopreservation in females and sperm cryopreservation in males, techniques undergoing experimental studies that could be implemented in the future like spermatogonial stem culture and transplantation of testicular tissue, the obstacles that we face that hinder the proper implementation of such practices and what measures can we take to overcome these obstacles to improve patient care and be better healthcare providers.

show abstract

Testicular germ cell tumors

Abstract: More effective treatments for intermediate risk, poor risk, and recurrent germ cell tumors need to be developed, while long-term toxicities of therapies need to be further modified. Given these challenges, active research on these fronts continues and remains a priority.

Cited by 4 publications

References 44 publications

Spermatogonial stem cell sensitivity to capsaicin: An in vitro study

Spermatogonial stem cell sensitivity to capsaicin: An in vitro study

Elevated serum levels of IGF-binding protein 2 in patients with non-seminomatous germ cell cancer: correlation with tumor markers α-fetoprotein and human chorionic gonadotropin

Filling the Gaps in Oncofertility Care by Addressing Challenges Faced by Patients and Providers

Contact Info

Product

Resources

About